Myriad Genetics, INTERLINK Partner To Enhance Access To Hereditary Cancer Testing
Myriad Genetics, Inc. (MYGN), a genetic and genomic tumor testing and precision medicine provider, and INTERLINK Care Management, ...
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.
Myriad Genetics secures patents for cancer MRD tests
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...